Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

MyMD Pharmaceuticals, Inc. - Common Stock (NQ:MYMD)

1.820 UNCHANGED
Last Price Updated: 3:38 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MyMD Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021
From MyMD Pharmaceuticals, Inc.
Via Business Wire
51 Biggest Movers From Yesterday
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... 
Via Benzinga
MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
68 Biggest Movers From Wednesday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Super CBD To the Rescue? This Company Thinks So
Photo by Kindel Media from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
From MyMD Pharmaceuticals, Inc.
Via Business Wire
A First-of-its-Kind Drug Candidate Targeting the Root Causes of Aging Could Soon Dominate Estimated $600 Billion Aging Market
Image on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.... 
Via Benzinga
Cramer Likes Azek And SoFi, But Said Owning This Stock Could Be Dreadful
On CNBC's "Mad Money Light... 
Via Benzinga
Benzinga Announces The 8 'Rising Star' Companies Being Featured On Its Next 'All Access' Show
Benzinga is thrilled to announce the guest lineup for our next All Access show, set to air Thursday, October 7 at 9:00 am ET. Thursday's Guest Lineup The theme... 
Via Benzinga
MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
From MyMD Pharmaceuticals, Inc.
Via Business Wire
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharma Stock Is Trading Higher As COVID-19 Candidate Effective In Suppressing Cytokine Storm
MyMD Pharmaceuticals Inc (NASDAQ: MYMD) announces that a human cell research study of its lead compound MYMD-1 found the drug to effectively suppress the cytokine storm... 
Via Benzinga
Exposures COVID-19
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Satsuma Pharmaceuticals (NASDAQ:STSA 
Via Benzinga
MyMD Pharmaceuticals Set to Join Russell Microcap® Index
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Schedules Business Update Conference Call
From MyMD Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.